05/08/2025 Immutep received positive feedback from the FDA for the late-stage development of Eftilagimod Alfa in SCCHN (Ref) Immutep received positive and constructive feedback from the US FDA regarding future clinical development of eftilagimod alpha (soluble LAG-3 protein) as a first-line Tx of R/M SCCHN with PD-L1 CPS <1. Based on available data from cohort B of the Ph2b TACTI-003 trial of efti + pembro in R/M SCCHN with CPS <1, the FDA agreed on the potential of the comb

08/07/2025 Adagene and ConjugateBio sign a partnership agreement to develop novel ADC (Ref) Adagene announced a partnership with ConjugateBio to provide a proprietary antibody for use in partner companies’ bispecific ADC development programs Under the terms of the agreement, Adagene will receive an undisclosed upfront payment, as well as milestone and royalty payments Adagene will provide an internally developed antibody for novel bispecific ADC development Adagene retains al

⭐ Summit Therapeutics, Inc. has reportedly been in partnership discussions with AstraZeneca and other major pharma companies for its sole asset, Ivonescimab (PD-1xVEGF BsAb) (Ref 1). ⭐ The potential deal, which could be valued at a staggering ~$15 billion (or higher?), would give a significant return on investment for Summit, which acquired the rights to ivonescimab from Akeso Biopharma in Dec 2022 in a transaction worth up to $5 billion, with a $500 million upfront payment (